The Fragile X mental retardation protein (FMRP) regulates neuronal RNA metabolism, and its absence or mutations leads to the Fragile X syndrome (FXS). The β-amyloid precursor protein (APP) is involved in Alzheimer's disease, plays a role in synapse formation, and is upregulated in intellectual disabilities. Here, we show that during mouse synaptogenesis and in human FXS fibroblasts, a dual dysregulation of APP and the α-secretase ADAM10 leads to the production of an excess of soluble APPα (sAPPα). In FXS, sAPPα signals through the metabotropic receptor that, activating the MAP kinase pathway, leads to synaptic and behavioral deficits. Modulation of ADAM10 activity in FXS reduces sAPPα levels, restoring translational control, synaptic morphology, and behavioral plasticity. Thus, proper control of ADAM10-mediated APP processing during a specific developmental postnatal stage is crucial for healthy spine formation and function(s). Downregulation of ADAM10 activity at synapses may be an effective strategy for ameliorating FXS phenotypes.

Dysregulated ADAM10-mediated processing of APP during a critical time window leads to Synaptic Deficits in Fragile X syndrome / E. Pasciuto, T. Ahmed, T. Wahle, F. Gardoni, L. D'Andrea, L. Pacini, S. Jacquemont, F. Tassone, D. Balschun, C.G. Dotti, Z. Callaerts Vegh, R. D'Hooge, U.C. Müller, M.M.G. Di Luca, B. De Strooper, C. Bagni. - In: NEURON. - ISSN 0896-6273. - 87:2(2015 Jul 15), pp. 382-398. [10.1016/j.neuron.2015.06.032]

Dysregulated ADAM10-mediated processing of APP during a critical time window leads to Synaptic Deficits in Fragile X syndrome

F. Gardoni;M.M.G. Di Luca;
2015

Abstract

The Fragile X mental retardation protein (FMRP) regulates neuronal RNA metabolism, and its absence or mutations leads to the Fragile X syndrome (FXS). The β-amyloid precursor protein (APP) is involved in Alzheimer's disease, plays a role in synapse formation, and is upregulated in intellectual disabilities. Here, we show that during mouse synaptogenesis and in human FXS fibroblasts, a dual dysregulation of APP and the α-secretase ADAM10 leads to the production of an excess of soluble APPα (sAPPα). In FXS, sAPPα signals through the metabotropic receptor that, activating the MAP kinase pathway, leads to synaptic and behavioral deficits. Modulation of ADAM10 activity in FXS reduces sAPPα levels, restoring translational control, synaptic morphology, and behavioral plasticity. Thus, proper control of ADAM10-mediated APP processing during a specific developmental postnatal stage is crucial for healthy spine formation and function(s). Downregulation of ADAM10 activity at synapses may be an effective strategy for ameliorating FXS phenotypes.
Settore BIO/14 - Farmacologia
15-lug-2015
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0896627315005954-main.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 3.46 MB
Formato Adobe PDF
3.46 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/290615
Citazioni
  • ???jsp.display-item.citation.pmc??? 28
  • Scopus 59
  • ???jsp.display-item.citation.isi??? 56
social impact